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EDITORIAL COMMENT
Dofetilide: Is the
Treatment Worse
Than the Disease?*
Michael R. Lauer, MD, PhD
San Jose and Stanford, California
On October 1, 1999, the U.S. Food and Drug Administra-
tion (FDA) approved dofetilide (Tikosyn) for the treatment
of persistent (nonparoxysmal) atrial fibrillation and flutter.
However, the FDA cautioned: “Because Tikosyn can cause
life-threatening ventricular arrhythmias, it should be re-
served for patients in whom atrial fibrillation/flutter is
highly symptomatic (1).” Dofetilide is the first new oral
antiarrhythmic drug preparation approved for use in the
U.S. in seven years, the last being d,l-sotalol in 1992. Unlike
its antiarrhythmic cousin, ibutilide—which is approved only
for parenteral administration and is used primarily for
conversion of atrial tachyarrhythmias in a monitored hos-
pital or emergency department setting—dofetilide is in-
tended for the long-term, outpatient treatment of atrial
fibrillation and atrial flutter.
See page 1100
Basic electrophysiology and pharmacology of dofetilide.
Dofetilide exerts its antiarrhythmic effects during cardiac
repolarization. During the normal cardiac action potential,
outward K1 currents overwhelm the decaying inward Na1
and Ca11 currents, thereby mediating cardiac repolariza-
tion. It has been demonstrated that the delayed rectifier
current, IK, consists of two components: a rapidly inactivat-
ing component, termed IKr, and a more slowly inactivating
component, termed IKs (2). IKr and IKs are each carried by
separate ion channel molecules (3). Dofetilide is a highly
selective blocker of IKr and, therefore, is classified as a pure
class III antiarrhythmic agent. The K1 channel blocking
effects of class III antiarrhythmic drugs, such as dofetilide,
result in a dose-dependent prolongation of the action
potential duration (4–7), and hence, the QT interval.
Prolongation of action potential duration is associated with
an increase in the effective refractory period of cardiac
tissues (8,9). While this increase in refractoriness is the
mechanism responsible for the antiarrhythmic effect of
dofetilide, excessive QT prolongation may trigger a disas-
trous form of polymorphic ventricular tachycardia, termed
torsade de pointes.
Dofetilide has an absolute bioavailability .90% (10).
Approximately 70% to 80% of the absorbed drug is excreted
unchanged by the kidney. In individuals with normal renal
function, the terminal elimination half-life is 8 to 10 h.
Dofetilide is also metabolized by the hepatic CYP3A4
enzyme system to a mixture of inactive metabolites that are
then excreted by the kidney. Total dofetilide clearance in
patients without severe renal insufficiency is proportional to
creatinine clearance; consequently, the patient’s dofetilide
dosage must be adjusted according to the creatinine clear-
ance. Even after correction for weight and renal function,
women have lower dofetilide clearance rates, resulting in
14% to 22% higher plasma concentrations (10).
A number of potential drug interactions have been
described (10). Verapamil increases peak plasma concentra-
tions of dofetilide after oral ingestion, primarily by increas-
ing intestinal blood flow. Cimetidine inhibits renal cationic
secretion of dofetilide and prolongs its half-life. The anti-
fungal agent ketoconazole, a potent inhibitor of the
CYP3A4 enzyme, prolongs the nonrenal clearance of
dofetilide and this interaction may become significant in
patients with renal dysfunction.
Clinical evaluation of dofetilide. The argument for the
safety and efficacy of dofetilide rests squarely on three large
clinical trials: the Danish Investigations on Arrhythmia and
Mortality on Dofetilide (DIAMOND) study (11,12), the
Symptomatic Atrial Fibrillation Investigative Research on
Dofetilide (SAFIRE-D) trial (13) and the European and
Australian Multicenter Evaluation Research on Atrial Fi-
brillation Dofetilide (EMERALD) study (10). At this
writing, only the results of the DIAMOND and
SAFIRE-D trials have been published in peer-reviewed
journals (11–13). All data were the subject of the public
FDA approval process (14).
The DIAMOND trials were double-blind and placebo-
controlled and designed to evaluate the efficacy and safety of
dofetilide in high risk patients with either congestive heart
failure (DIAMOND-CHF) or recent myocardial infarction
(DIAMOND-MI). These were mortality trials, and specific
antiarrhythmic effects were not primary end points.
DIAMOND-CHF randomized 1,518 patients with abnor-
mal left ventricular function (ejection fraction ,35%) de-
fined echocardiographically. DIAMOND-MI randomized
1,510 patients who had a myocardial infarction within the
previous seven days and had a left ventricular ejection
fraction ,35%. Patients in both studies were randomized to
regimens of either dofetilide 500 mg twice daily or to
matching placebo. By protocol, patients with atrial fibrilla-
tion or flutter received half the standard dose, namely,
250 mg twice daily. Downward dosage adjustment was
permitted for patients with reduced creatinine clearance and
for QT prolongation. Analysis of total mortality was per-
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formed with the use of an intention-to-treat approach. In
DIAMOND-CHF, 311 of 762 (41%) dofetilide group
patients died compared with 317 of 756 (42%) placebo
group patients (p 5 NS). In DIAMOND-MI, 230 of 749
(31%) dofetilide group patients and 243 of 761 (32%)
placebo group patients died (p 5 NS). These results
suggested that dofetilide did not affect mortality in a group
of high risk patients with congestive heart failure and left
ventricular dysfunction (11,12).
The outcomes of 506 patients with persistent atrial
fibrillation who entered the DIAMOND studies were
analyzed as part of a DIAMOND substudy. All patients
were randomly assigned to receive dofetilide (250 mg twice
daily) or placebo. Patients with persistent atrial fibrillation
at entry were followed on their assigned therapy for one
month. If they remained in atrial fibrillation, they were
eligible for cardioversion. During the first 30 days of
treatment, 56 of 249 patients taking dofetilide versus 7 of
257 patients receiving placebo converted to sinus rhythm.
An additional 50 patients receiving dofetilide and 28 pa-
tients receiving placebo were electrically cardioverted.
Among those patients in whom sinus rhythm was restored,
35% of dofetilide patients versus 84% of placebo patients
had relapses into atrial fibrillation. Finally, for all DIA-
MOND patients who were originally in sinus rhythm, the
dofetilide group also had a significantly lower incidence of
new-onset atrial fibrillation (2% vs. 10%).
In the SAFIRE-D trial, 325 patients with persistent
atrial fibrillation or flutter were hospitalized and random-
ized to therapy with either placebo or dofetilide at one of
three doses: 125 mg, 250 mg or 500 mg twice daily.
Dofetilide dose was adjusted for QTc and creatinine clear-
ance prior to hospital discharge. Using intention-to-treat
analysis, the results showed that dofetilide at doses of
250 mg or 500 mg was more effective than placebo at
converting patients with atrial flutter or fibrillation to sinus
rhythm, but only the 500-mg dose was more effective than
placebo at maintaining sinus rhythm for one year.
The EMERALD study was a randomized, double-blind,
placebo-controlled trial of 546 patients with persistent atrial
fibrillation. Patients were randomized to receive placebo, or
dofetilide at one of three doses: 125 mg, 250 mg or 500 mg
twice daily, or sotalol 80 mg twice daily. Between 76% and
90% of patients in the five groups achieved sinus rhythm
after either pharmacologic or electrical cardioversion and
entered the maintenance portion of the study. At 1 year, the
specified primary end point of the study, 30%, 45% and 51%
of the 125 mg, 250 mg and 500 mg dofetilide groups,
respectively, 38% of the sotalol group, and 16% of the
placebo group remained in sinus rhythm, free of recurrent
atrial fibrillation. All of the active drug groups were statis-
tically different from placebo.
Does dofetilide expose patients to a significant long-term
risk of ventricular proarrhythmia? Dofetilide prolongs the
action potential duration and QT interval in a
concentration-dependent fashion (6,8). Reports of the early
incidence of torsade de pointes by QT-prolonging antiar-
rhythmic agents range from 0.5% to 8% (15–19). During
dofetilide clinical studies, treatment was initiated during
in-hospital monitoring until presumed steady state had been
achieved. QT intervals were measured before each dose and
a downward dose adjustment was permitted. Before 1994,
however, patients participating in the dofetilide trials were
assigned doses without regard to their baseline creatinine
clearance, and doses up to 750 mg twice daily were allowed.
After the occurrence of a number of cases of torsade de
pointes, dosage was adjusted based on creatinine clearance
and the 750 mg twice-daily dose level was eliminated.
Following these changes, a substantial reduction in the
incidence of torsade de pointes was noted. In DIAMOND-
CHF, the incidence of torsade de pointes decreased from 7
of 146 (4.8%) to 18 of 616 (2.9%) using the amended
protocol. Overall, torsade de pointes ($10 beats) was
observed in 25 of 762 (3.3%) DIAMOND-CHF patients, 7
of 749 (0.9%) DIAMOND-MI patients, 12 of 1,377 (0.9%)
patients in supraventricular arrhythmia trials and 11 of
443 (2.5%) patients in ventricular tachycardia trials (10).
Most, but not all, documented episodes of torsade de
pointes occurred during the in-hospital therapy initiation
period; therefore, excess fatalities were rare. Risk factors for
torsade de pointes included a higher dose, female gender,
baseline QT .450 ms, greater QTc increase during loading
and a history of a sustained ventricular tachycardia. It is
important to note that patients with QTc .460 ms, resting
heart rates ,50 beats/min or a history of polymorphic
ventricular tachycardia were excluded from these trials.
While the short-term risk of dofetilide-induced torsade
de pointes appears well established from available clinical
data, the long-term proarrhythmic risk of this agent is not
known. Indeed, assessment of the long-term proarrhythmic
potential of any antiarrhythmic agent is extremely difficult,
especially in a population of patients with significant left
ventricular dysfunction and a well established history of
ventricular tachyarrhythmias, similar to the patients evalu-
ated by Mazur et al. (20) and reported in the current issue
of the Journal. This evaluation of risk is even more prob-
lematic when the proarrhythmic potential is (at least partly)
related to the QT interval duration at the time of the
suspicious arrhythmic event. Since the QT interval duration
may be dynamic and can be measured only using surface
electrocardiography, verification of QT interval prolonga-
tion at the time of the presumed proarrhythmic event may
be difficult.
Nevertheless, to my knowledge, the report by Mazur et al.
(20) is the first to evaluate the long-term antiarrhythmic and
proarrhythmic effects of dofetilide in patients with signifi-
cant left ventricular dysfunction who have received an
implantable cardioverter-defibrillator (ICD) system for
treatment of ventricular tachyarrhythmias. They analyzed
data from a multicenter study of 174 ICD patients who
were randomly assigned to receive placebo or dofetilide. The
clinical profile of these patients appears similar to the typical
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ICD patient: 88% male, 77% with ejection fraction ,35%,
with the majority having had ventricular tachycardia (79%)
as opposed to ventricular fibrillation (21%). The starting
dose of dofetilide, 500 mg twice daily, was adjusted down-
ward based on estimates of creatinine clearance, or if the
corrected QT interval increased by 15% over baseline after
starting treatment with the drug. During periods of in-
hospital treatment, patients were monitored with continu-
ous ECG recording. During a planned one-year period of
drug treatment, 131 of the 174 patients received therapy
from their ICD (either antitachycardia pacing or shock).
Episodes of ventricular tachyarrhythmias detected and
treated by the ICD were analyzed using intracardiac elec-
trograms stored in the ICD devices. The ICD devices do
not record nonsustained episodes of tachycardia that fail to
satisfy programmed detection criteria (rate or duration).
Unfortunately, in the present study, there was no standard-
ization of ICD programming for rate detection zones,
tachycardia duration requirements or the rate of back-up
antibradycardia pacing. Using prospectively developed cri-
teria, the stored episodes were scored in a blinded fashion as
monomorphic ventricular tachycardia, polymorphic ventric-
ular tachycardia or ventricular fibrillation. In addition, the
onset of each detected episode of tachycardia was declared
as pause-dependent if a specifically defined “short-long-
short” sequence was seen at the initiation of the tachycardia.
Stored electrograms showing episodes of pause-dependent
polymorphic ventricular tachycardia may be equivalent to
pause-dependent torsade de pointes. However, accurate
measurements of the QT interval duration cannot be made
from intracardiac recordings, but instead would require a
simultaneously obtained surface ECG.
Mazur et al. (20) found that ICD patients receiving
dofetilide had an increased incidence of total episodes of
torsade de pointes (recorded by surface ECG) and pause-
dependent polymorphic ventricular tachycardia (recorded by
ICD device) when both the in-hospital loading and
follow-up periods were included, compared with a clinically
similar group receiving the placebo (p , 0.05). However,
while 11% (10/87) of the dofetilide patients had episodes
that occurred after the prescribed in-hospital loading period,
the long-term incidence of pause-dependent polymorphic
ventricular tachycardia was not statistically greater in the
dofetilide group (11%) than the placebo group (5/87 pa-
tients, 6%). Whether all these late episodes of pause-
dependent polymorphic ventricular tachycardia were really
torsade de pointes cannot be determined since the ICD
electrogram evidence of pause-dependent polymorphic ven-
tricular tachycardia could not be correlated with simulta-
neous prolongation of QT interval duration. It is, in fact,
unlikely that all these pause-dependent episodes were tor-
sade de pointes because patients receiving the placebo (and
who would not be expected to have QT prolongation and
torsade de pointes) had a significant rate of pause-
dependent polymorphic ventricular tachycardia (6%). It is
possible that all patients with significant left ventricular
dysfunction share a common risk for pause-dependent
polymorphic ventricular tachycardia (regardless of whether
it is “true” torsade de pointes due to QT prolongation), even
in the absence of treatment with QT interval-prolonging
agents. This suggestion is supported by the observation that
in 13 patients (four receiving dofetilide, nine receiving
placebo), the first QTc recorded after an episode of pause-
dependent polymorphic ventricular tachycardia was not
statistically different in the dofetilide-treated patients com-
pared with the patients receiving the placebo.
Taken together, this and previously reported data (10)
suggest that the risk of dofetilide-induced torsade de pointes
is low when using strict dosing criteria guided by the
patient’s renal function, QT interval and concomitant drug
therapy. However, as always, while the risk is small, it
should be balanced against the risk posed to the patient by
the target arrhythmia and the alternative treatment options
available. Finally, while not statistically significant, the trend
of the long-term data presented by Mazur et al. (20) should
alert cardiologists and cardiac electrophysiologists to the
potential for long-term proarrhythmia associated with the
use of IKr blocking agents, particularly in patients with
significant left ventricular dysfunction. Clearly further study
with more patients and longer follow-up will be necessary.
What is the role of dofetilide in the management of
cardiac arrhythmias? In the past 15 years, there has been a
revolution in the treatment of cardiac arrhythmias. The two
greatest achievements of modern therapeutic cardiac elec-
trophysiology have been the development of the radiofre-
quency electrode catheter ablation technique and the ICD
system. Most forms of supraventricular tachycardia, includ-
ing atrioventricular nodal reentrant tachycardia, atrioven-
tricular reciprocating tachycardia utilizing an accessory con-
nection and many forms of atrial flutter and atrial
tachycardia are now routinely cured by catheter ablation
using radiofrequency energy. Even selected patients with
paroxysmal atrial fibrillation may now be curable with
radiofrequency ablation (21). Patients with persistent or
chronic atrial fibrillation with rapid, medically uncontrolla-
ble ventricular rates that threaten the development of a
tachycardia-induced cardiomyopathy may be best managed
by complete ablation of the atrioventricular junction fol-
lowed by implantation of a permanent pacemaker system. A
large percentage of patients with structurally normal hearts
and idiopathic right or left ventricular tachycardias can be
cured using radiofrequency ablation. The ICD systems are
routinely implanted for secondary prevention in patients
with structural heart disease who have suffered an episode of
sustained ventricular tachycardia or ventricular fibrillation.
Also, ICD systems are increasingly implanted for primary
prevention in high risk patients with inducible ventricular
tachycardia. Studies are currently in progress to evaluate the
empiric implantation of ICD systems in high risk patients
without electrophysiologic guidance. Consequently, drug
therapy for patients with cardiac arrhythmias has been
largely marginalized to patients with atrial fibrillation, ICD
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patients receiving frequent, clinically appropriate shock or
pacing therapies, or patients with non-life-threatening ar-
rhythmias that remain uncured after attempts at catheter
ablation.
The traditional limitations of drug therapy for cardiac
arrhythmias have been the low efficacy of the available
agents and the potential for side effects, particularly ventric-
ular proarrhythmia. In general, treatment of ventricular or
supraventricular tachyarrhythmias using class IA or IC
drugs in patients with significant structural heart disease is
contraindicated (22). The class III agent d,l-sotalol is also
problematic in patients with structural heart disease given
evidence that treatment of these patients with the pure
dextroisomer of sotalol was associated with excess mortality,
possibly due to torsade de pointes (23). Even in ICD
patients with significant left ventricular dysfunction, drug-
induced bradycardia and congestive heart failure may limit
treatment with racemic sotalol. From the standpoint of
proarrhythmia potential, amiodarone is considered the saf-
est antiarrhythmic agent for treatment of cardiac arrhyth-
mias (24). While amiodarone may cause torsade de pointes,
the reported incidence is rare. However, amiodarone has
other, potentially significant limitations, including organ
toxicity and significant bradyarrhythmias.
With this backdrop, dofetilide has arrived on the scene.
Atrial fibrillation and atrial flutter are not considered to be
imminently life-threatening arrhythmias. While patients
with these conditions are at increased risk of embolic stroke
or tachycardia-induced cardiomyopathy, these atrial ar-
rhythmias do not cause sudden arrhythmic death (in the
absence of a manifest accessory pathway). Consequently,
physicians and their patients with atrial tachyarrhythmias
must carefully evaluate any potential treatment option that
has a demonstrated life-threatening proarrhythmic poten-
tial. For patients with typical clockwise or counterclockwise
atrial flutter, or other readily curable supraventricular tachy-
arrhythmias, radiofrequency catheter ablation appears to be
preferable to long-term treatment with dofetilide. In expe-
rienced hands, the risk of this curative treatment option is
extremely low with very high success rates for these arrhyth-
mias. Alongside class IC and III agents, dofetilide may have
a role in the treatment of atrial fibrillation in patients
lacking significant structural heart disease. For selected
patients with minimal or no structural heart disease and
evidence of a focal origin for their atrial fibrillation, a
curative ablation procedure should also be considered, par-
ticularly for those patients who have failed to respond to
medical therapy. The years of clinical experience with
amiodarone, in my opinion, still make it the first choice for
medical treatment of highly symptomatic atrial fibrillation
in patients with significant left ventricular dysfunction.
According to the dofetilide package insert (10), the
incidence of torsade de pointes ($10 beats) in the closely
monitored and controlled clinical trials ranged as high as
3.3% in patients with structural heart disease. I believe the
“real world” risk of torsade de pointes is as yet undefined in
this population of patients, particularly in the routine
environment of day-to-day clinical medicine in which reg-
ular patient follow-up is not assured, medical noncompli-
ance is the norm and renal function in elderly diabetic
patients with congestive heart failure may change with little
advance notice. In addition, patients may self-treat with any
number of over-the-counter medications and may unavoid-
ably receive treatments from a wide variety of unsuspecting
clinicians who may prescribe a variety of antibiotics, anti-
histamines, or antiulcer medications or change the doses of
previously prescribed agents, including potassium, diuretics
and digoxin. In a world filled with imperfect patients and
imperfect doctors, more clinical experience and research is
necessary before judging that dofetilide is as safe and as
effective as amiodarone in this patient population. Clearly, a
head-to-head comparison of amiodarone and dofetilide for
the treatment of atrial fibrillation in this group of patients
would be welcome.
Ironically, dofetilide may find its most useful niche in the
treatment of problematic ventricular tachyarrhythmias in
patients with ICD systems. As noted by Mazur et al. (20),
dofetilide treatment was associated with a trend to a
decreased frequency of multiple episodes of monomorphic
ventricular tachycardia, suggesting that the agent may re-
duce the number of recurrences of this type of ventricular
tachycardia. In addition, dofetilide treatment was associated
with a significantly increased rate of successful antitachycar-
dia pacing in ICD patients. These data are consistent with
two small studies showing dofetilide was also effective in
acutely suppressing inducible sustained ventricular tachycar-
dia during serial electrophysiologic testing in approximately
45% of patients (25,26). Under the protective cover of an
ICD device, electrophysiologists and cardiologists may be
more accepting of potential rare episodes of ventricular
proarrhythmia, as long as the antiarrhythmic effects of the
dofetilide prove beneficial. Consequently, many electro-
physiologists and cardiologists are likely to gain valuable
clinical experience with dofetilide while using the drug to
manage problematic atrial or ventricular tachyarrhythmias
in their ICD patients.
Regardless of the revolutionary and evolutionary changes
in interventional electrophysiology, there will always be a
need for effective and safe antiarrhythmic drugs. Patients
undergoing unsuccessful attempts at an ablative cure, as well
as ICD patients experiencing frequent, painful, but clini-
cally appropriate shocks, will require palliative antiarrhyth-
mic drug therapy. This need may only increase as our
population ages and ICD implantation is extended to a role
in primary prevention of sudden arrhythmic death in high
risk patient groups. Consequently, it is possible that the
pharmaceutical industry may seek to employ even greater
numbers of patients with implantable ICD systems in
clinical trials of antiarrhythmic drugs, both to evaluate the
effectiveness of these agents to suppress ventricular arrhyth-
mias, and also to investigate the antiarrhythmic efficacy and
proarrhythmic potential of these agents in the case of
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non-life-threatening, but difficult-to-treat, atrial tachy-
arrhythmias.
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